GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals announced a change in its top finance leadership. The current CFO and Whole-Time Director, Mr. Juby Chandy, will step down from both roles effective March 11, 2026, to take up a new role leading APAC Finance within the GSK Group. In his place, Mr. Ronojit Biswas (DIN 07684843) has been appointed as the new Whole-Time Director & CFO for a three-year term starting April 1, 2026. Ronojit is a GSK veteran with over 25 years of experience across India, Vietnam, Singapore, Brazil, and the UK, and most recently served as Senior Finance Director – Global Product Strategy in Singapore. The company acknowledged Chandy's contributions in strengthening the financial position and governance during his tenure.
This is a smooth, internally managed CFO transition within the GSK Group with no governance red flags, likely to be neutral to mildly positive as the incoming CFO is a seasoned insider. Shareholders should note a brief overlap period between March 11 and April 1 when the CFO position will be vacant.